Mineralys Therapeutics(MLYS)2025-02-12 12:07Financial Performance - Cash, cash equivalents, and investments were 239.0 million as of December 31, 2023[6] - Net loss for the year ended December 31, 2024, was 71.9 million for the year ended December 31, 2023[11] - Total other income, net for the year ended December 31, 2024, was 12.8 million in 2023[9] - Total assets decreased to 251.636 million, representing a decrease of about 18.1% year-over-year[27] - Total liabilities increased to 10.482 million, an increase of approximately 39.9% year-over-year[27] - Total stockholders' equity decreased to 241.154 million, a decline of about 20.7% year-over-year[27] Expenses - Research and Development (R&D) expenses for the year ended December 31, 2024, were 70.4 million in 2023[7] - General and Administrative (G&A) expenses rose to 14.3 million for 2023[8] Clinical Trials and Studies - Anticipated topline data from the pivotal Advance-HTN trial in March 2025 and the Launch-HTN trial in mid-2025[1] - Enrollment in the Explore-CKD Phase 2 trial has been completed, with topline data expected in Q2 2025[1] - Initiation of the Phase 2 trial for lorundrostat in patients with moderate-to-severe obstructive sleep apnea and hypertension is planned for Q1 2025[1] - Lorundrostat demonstrated approximately a 70% reduction in plasma aldosterone concentration in hypertensive subjects[19] Cash Flow and Funding - The company believes its current cash and investments will fund planned clinical studies through the first quarter of 2026[6] - Cash, cash equivalents, and investments decreased to 239.049 million, a decline of approximately 17.1% year-over-year[27]